Table 1 |
|||
|
Baseline characteristics of patients with type 2 diabetes as divided into poor and good glycemic control |
|||
|
Poor glycemic control |
Good glycemic control |
P value |
|
|
|
|||
|
Number |
23 |
13 |
- |
|
Age (years) |
59.7 ± 13.2 (31-86) |
64.7 ± 13.2 (41-86) |
0.287 |
|
Sex (male:female) |
9:14 |
5:08 |
- |
|
BMI (kg/m2) |
23.8 ± 2.8 |
21.6 ± 4.5 |
0.516 |
|
Duration of diabetes (years) |
6.7 ± 4.3 (1-15) |
5.2 ± 4.3 (1-13.4) |
0.433 |
|
Systolic blood pressure (mmHg) |
126.2 ± 18 (100-170) |
134.4 ± 16 (110-150) |
0.251 |
|
Diastolic blood pressure (mmHg) |
79.1 ± 8.9 (60-90) |
76.7 ± 7.1 (70-90) |
0.582 |
|
HbA1C (%) |
9.2 ± 1.4 (7-12.2) |
6.2 ± 0.5 (5.3-6.6) |
< 0.001 |
|
FBS (mmol/l) |
8.9 ± 1.8 (5.8-11.8) |
6.7 ± 0.8 (5.6-8.2) |
< 0.001 |
|
Total cholesterol (mg/dl) |
175.9 ± 31.9 (134-242) |
191.8 ± 42.6 (148-264) |
0.314 |
|
LDL cholesterol (mg/dl) |
98.6 ± 25.3 (61-146) |
125 ± 41.9 (76-215) |
0.936 |
|
HDL cholesterol (mg/dl) |
51.8 ± 12.8 (35-75) |
48 ± 13.6 (32-73) |
0.977 |
|
Triglyceride (mg/dl) |
137.8 ± 70 (54-310) |
218.5 ± 121.5 (100-340) |
0.124 |
|
Therapy |
|||
|
Statin [n (%)] |
15 (65) |
7 (53) |
- |
|
ACEI/ARB [n (%)] |
4 (17) |
3 (23) |
- |
|
Aspirin [n (%)] |
1 (4) |
1 (7) |
- |
|
OHA [n (%)] |
20 (87) |
10 (77) |
- |
|
Insulin [n (%)] |
1 (4) |
1 (7) |
- |
|
OHD + Insulin [n (%)] |
2 (8) |
- |
- |
|
|
|||
|
Data are presented as mean ± SD, percentage or median (interquartile range); ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blockers; BMI, body-mass index; FBS, fasting blood sugar; HbA1C, glycosylated hemoglobin; HDL, high-density lipoprotein; LDL, low-density lipoprotein; OHA, oral hypoglycemic agent. |
|||
|
Churdchomjan et al. BMC Endocrine Disorders 2010 10:5 doi:10.1186/1472-6823-10-5 |
|||
